Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate.
Oukseub LeeMegan E SullivanYanfei XuChiara RogersMiguel MuzzioIrene HelenowskiAli ShidfarZexian ZengHari SinghalBorko JovanovicNora HansenKevin P BethkePeter H GannWilliam GradisharJ Julie KimSusan E ClareSeema Ahsan KhanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Patients treated with telapristone acetate whose Ki67 decreased by ≥30% demonstrated a selective antiproliferative signal, with a potentially important effect on HER2 amplicon genes. Evaluation of SPRMs in a neoadjuvant trial is merited, with attention to predictors of response to SPRM therapy, and inclusion of pre- and postmenopausal women.
Keyphrases
- phase ii
- postmenopausal women
- placebo controlled
- clinical trial
- open label
- phase iii
- early stage
- bone mineral density
- double blind
- study protocol
- rectal cancer
- small molecule
- working memory
- neoadjuvant chemotherapy
- genome wide
- phase ii study
- locally advanced
- randomized controlled trial
- stem cells
- transcription factor
- gene expression
- cell therapy
- squamous cell carcinoma
- sentinel lymph node
- bioinformatics analysis
- genome wide analysis